Literature DB >> 23075765

Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction.

Daisaku Nakatani1, Yasuhiko Sakata, Shinichiro Suna, Masaya Usami, Sen Matsumoto, Masahiko Shimizu, Satoru Sumitsuji, Shigeo Kawano, Yasunori Ueda, Toshimitsu Hamasaki, Hiroshi Sato, Shinsuke Nanto, Masatsugu Hori, Issei Komuro.   

Abstract

BACKGROUND: In the percutaneous coronary intervention (PCI) era, little evidence exists regarding the incidence, predictors and long-term mortality of recurrent myocardial infarction (Re-MI) following discharge for acute myocardial infarction (AMI). METHODS AND
RESULTS: A total of 7,870 patients who survived AMI were studied with a median follow-up period of 3.9 years: 353 patients (4.5%) experienced Re-MI, with 7 of those dying within 30 days, which was classified as fatal Re-MI. The incidence of Re-MI per year was 2.65% for the first year, and 0.91-1.42% thereafter up to 5 years. Multivariate Cox regression analyses revealed that predictors of Re-MI were diabetes mellitus (hazard ratio (HR): 2.079, P<0.001), history of MI (HR: 1.767, P=0.001), and advanced age (HR: 1.021, P=0.001). These 3 predictors remained significant when angiographic and procedural parameters were incorporated into the analyses. The incidence and adjusted risk of Re-MI increased when these variables were clustered (P<0.001). The all-cause mortality rate was significantly higher in patients with Re-MI than in those without (HR: 2.206, P<0.001).
CONCLUSIONS: In post-AMI patients treated in the PCI era, the incidence of Re-MI is low compared with that reported during the past 30 years. Patients' clinical factors of diabetes mellitus, history of MI, and advanced age appear to affect the occurrence of Re-MI after hospital discharge, and Re-MI still carries a risk for subsequent mortality.

Entities:  

Mesh:

Year:  2012        PMID: 23075765     DOI: 10.1253/circj.cj-11-1059

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  21 in total

1.  The changing epidemiology of myocardial infarction in Olmsted County, Minnesota, 1995-2012.

Authors:  Yariv Gerber; Susan A Weston; Ruoxiang Jiang; Véronique L Roger
Journal:  Am J Med       Date:  2014-09-28       Impact factor: 4.965

2.  Safety of percutaneous coronary intervention in patients with acute ischemic stroke/transient ischemic attack and acute coronary syndrome.

Authors:  Tobias Zeus; Ulrike Ketterer; Daniela Leuf; Lisa Dannenberg; Florian Bönner; Rabea Wagstaff; Michael Gliem; Sebastian Jander; Malte Kelm; Amin Polzin
Journal:  Clin Res Cardiol       Date:  2015-10-29       Impact factor: 5.460

3.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

Review 4.  [Secondary prevention with antiplatelet therapy in cardiac rehabilitation].

Authors:  Maria M Wanitschek; Hannes F Alber
Journal:  Wien Med Wochenschr       Date:  2017-01-13

5.  Are beta blockers still necessary for all survivors of acute myocardial infarction?

Authors:  Daisaku Nakatani; Yasuhiko Sakata
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

6.  A case series of acute renal infarction at a single center in Japan.

Authors:  Tasuku Nagasawa; Ken Matsuda; Yoichi Takeuchi; Hirotaka Fukami; Hiroyuki Sato; Ayako Saito; Yoichiro Chikamatsu; Yasumichi Kinoshita
Journal:  Clin Exp Nephrol       Date:  2015-09-16       Impact factor: 2.801

7.  Effect of CSL112 (apolipoprotein A-I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross-study comparison.

Authors:  Bo Zheng; Shinya Goto; Regina Clementi; John Feaster; Danielle Duffy; Penelope Dalitz; Jolanta Airey; Serge Korjian; Michael A Tortorici; John Roberts; C Michael Gibson
Journal:  Clin Transl Sci       Date:  2022-08-07       Impact factor: 4.438

8.  Modelling the cost-effectiveness of pharmacist-managed anticoagulation service for older adults with atrial fibrillation in Singapore.

Authors:  Wen Bing Brandon Chua; Hua Heng McVin Cheen; Ming Chai Kong; Li Li Chen; Hwee Lin Wee
Journal:  Int J Clin Pharm       Date:  2016-07-26

Review 9.  [Platelet aggregation inhibitors and anticoagulants during ophthalmic interventions].

Authors:  N Feltgen; H Hoerauf; W Noske; A Hager; J Koscielny
Journal:  Ophthalmologe       Date:  2016-12       Impact factor: 1.059

Review 10.  Mind-Body Medicine in the Secondary Prevention of Coronary Heart Disease.

Authors:  Holger Cramer; Romy Lauche; Anna Paul; Jost Langhorst; Andreas Michalsen; Gustav Dobos
Journal:  Dtsch Arztebl Int       Date:  2015-11-06       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.